Neurochemical biomarkers in the differential diagnosis of movement disorders
Tóm tắt
In recent years, the neurochemical analysis of neuronal proteins in cerebrospinal fluid (CSF) has become increasingly accepted for the diagnosis of neurodegenerative dementia diseases such as Alzheimer's disease and Creutzfeldt–Jakob disease. CSF surrounds the central nervous system, and in the composition of CSF proteins one finds brain‐specific proteins that are prioritized from blood‐derived proteins. Levels of specific CSF proteins could be very promising biomarkers for central nervous system diseases. We need the development of more easily accessible biomarkers, in the blood. In neurodegenerative diseases with and without dementia, studies on CSF and blood proteins have investigated the usefulness of biomarkers in differential diagnosis. The clinical diagnoses of Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration still rely mainly on clinical symptoms as defined by international classification criteria. In this article, we review CSF biomarkers in these movement disorders and discuss recent published reports on the neurochemical intra vitam diagnosis of neurodegenerative disorders (including recent CSF α‐synuclein findings). © 2009 Movement Disorder Society
Từ khóa
Tài liệu tham khảo
Reiber H, 2006, Neurlogische Labordiagnostik
Cleveland DW, 1979, Conservation of microtubule associated proteins. Isolation and characterization of tau and the high molecular weight microtubule associated protein from chicken brain and from mouse fibroblasts and comparison to the corresponding mammalian brain proteins, JBiol Chem, 254, 12670, 10.1016/S0021-9258(19)86366-4
Glenner GG, 1984, The amyloid deposits in Alzheimer's disease: their nature and pathogenesis, Appl Pathol, 2, 357
Jellinger KA, 2001, The pathology of Parkinson's disease, Adv Neurol, 86, 55
Chesselet MF, 1983, Somatostatin regulates dopamine release in rat striatal slices and cat caudate nuclei, J Neurosci, 3, 232, 10.1523/JNEUROSCI.03-01-00232.1983
Yoshinaga J, 1989, Acetylcholinesterase activity in CSF in senile dementia of Alzheimer type, vascular dementia, and Parkinson's disease, Rinsho Shinkeigaku, 29, 376
Polinsky RJ, 1988, Low lumbar CSF levels of homovanillic acid and 5‐hydroxyindoleacetic acid in multiple system atrophy with autonomic failure, J Neurol Neurosurg Psychiatry, 51, 914, 10.1136/jnnp.51.7.914
Konagaya M, 1992, [CSF acetylcholinesterase activity in central neurological diseases involving cholinergic systems], Rinsho Shinkeigaku, 32, 266
de Jong PJ, 1984, CSF GABA levels in Parkinson's disease, Adv Neurol, 40, 427
Chase TN, 1976, Biochemical aids in the diagnosis of Parkinson's disease, Ann Clin Lab Sci, 6, 4
Extein I, 1976, 14C‐homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C‐L‐dopa, Biol Psychiatry, 11, 227
Kurlan R, 1988, Cerebrospinal fluid homovanillic acid and parkinsonism in Huntington's disease, Ann Neurol, 24, 282, 10.1002/ana.410240221
Fukuda H, 1989, [Study on the concentration of 5‐hydroxyindoleacetic acid (5‐HIAA) in the lumbar cerebrospinal fluid (CSF) in neurological diseases], Rinsho Shinkeigaku, 29, 1192
Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease, 1995, Parkinson Study Group, Arch Neurol, 52, 237
Gonzalez‐Quevedo A, 1993, Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system, Bol Estud Med Biol, 41, 13
Kanemaru K, 1998, Cerebrospinal fluid homovanillic acid levels are not reduced in early corticobasal degeneration, Neurosci Lett, 245, 121, 10.1016/S0304-3940(98)00181-5
Krygowska‐Wajs A, 1997, Salsolinol, 3‐O‐methyl‐dopa and homovanillic acid in the cerebrospinal fluid of Parkinson patients, Neurol Neurochir Pol, 31, 875
Botez MI, 2001, Biogenic amine metabolites and thiamine in cerebrospinal fluid in heredo‐degenerative ataxias, Can J Neurol Sci, 28, 134, 10.1017/S0317167100052811
Cramer H, 1984, Analysis of neurotransmitter metabolites and adenosine 3',5'‐monophosphate in the CSF of patients with extrapyramidal motor disorders, Adv Neurol, 40, 431
Jimenez‐Jimenez FJ, 1998, Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease, J Neural Transm, 105, 497, 10.1007/s007020050073
Ilic T, 1998, Oxidative stress and Parkinson's disease, Vojnosanit Pregl, 55, 463
Bostrom F, 2008, CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies, Neurobiol Aging
Yamada T, 1993, Concentration of neural thread protein in cerebrospinal fluid from progressive supranuclear palsy and Parkinson's disease, Jpn J Psychiatry Neurol, 47, 631
Urakami K, 2002, Corticobasal degeneration and progressive supranuclear palsy‐‐biochemical marker, Rinsho Shinkeigaku, 42, 1162
Mollenhauer B, 2007, A platform for the quantification of alpha‐synuclein in cerebrospinal fluid: evidence for a potential biomarker for synucleinopathies, Neurodegenerative Diseases, 4, 1
Mollenhauer B, 2006, Proteome analysis of cerebrospinal fluid by mass spectrometry: A platform for marker development in synucleinopathies, Movement Disorders, 21, P780
Huang RP, 2004, Cytokine protein arrays, Methods Mol Biol, 264, 215